Dr. Saad founded Alkeus Pharmaceuticals with the goal of developing sight-saving, transformative medicines for the most serious and untreatable causes of blindness. Prior to Alkeus Pharma, he was partner in a boutique life sciences management and consulting firm in New York City, providing business and strategic guidance to biotechnology and pharmaceutical companies. He was previously at Proteus Venture Partners, an early stage, California based venture fund focused on stem cells and regenerative medicine.
Dr. Saad holds a PhD focused on tissue engineering from MIT, a certificate of Financial Technology from MIT Sloan School of Management, a MS in Mechanical Engineering from MIT, a BS and MS in Applied Mathematics from University of Paris VI, and is a graduate from Ecole Polytechnique, Paris, with a concentration in organic chemistry and physics.
Dr. Boger joined Alkeus Pharma as Executive Chairman in May 2012, three years after he retired as Chief Executive Officer of Vertex Pharmaceuticals. As founder of Vertex, he led the company’s efforts to develop science-based transformative medicines for over 20 years, transforming the firm into a successful global enterprise counting over 2,000 employees today. Vertex's gripping story was profiled in two books: The Billion-Dollar Molecule (1995) and The Antidote (2014). Dr. Boger was also a pioneer in setting up alliances between Pharma and disease-focused foundations, which resulted in the commercialization of the first drug to address the genetic defect associated with Cystic Fibrosis.
Dr. Boger continues to serve on the board of Vertex. He is also the Chair of the Board of Harvard Medical School, Chair of the Board of Trustees at Wesleyan University, Chair of NEHI (the Network for Healthcare Innovation), board member of the Biotechnology Industry Organization (BIO), of the Whitehead Institute for Biomedical Research, the Hastings Center and the Massachusetts Life Sciences Center. He is also the Chair of the Board of the Celebrity Series (Boston), Vice-Chair of the Alliance for Business Leadership, Vice-Chair of the Museum of Science (Boston), and serves on additional boards such as the Harvard Board of Overseers, the American Civil Liberties Union of Massachusetts Foundation, the Science Advisory Council of WGBH, the Massachusetts Workforce Investment Board and MassChallenge.
Dr. Boger began his industry career at Merck and holds a PhD degree in chemistry from Harvard university and a BA in chemistry and philosophy from Wesleyan University.
Dr. Washington is the co-founder of Alkeus Pharma. He is Assistant Professor at Columbia University Medical Center in the Department of Ophthalmology. His research focuses on understanding how unavoidable environmental phenomena such as light, gravity, magnetic fields and diet influence and dictate human health on a molecular level. His group uses this knowledge to better understand the origins of disease and design future medicines. Dr. Washington has published in the fields of ophthalmology, biology and chemistry, and was featured in several articles for his thought provoking scientific ideas.
Dr. Washington holds a PhD in organic chemistry from UCLA and a BA in chemistry from Bard College. He completed postdoctoral work at Columbia University and trained under the mentorship of Koji Nakanishi, Nick Turro (Columbia University), Ken Houk (UCLA) and Hilton Weiss (Bard).